Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.57 |
| ▸ | SMO | Q99835 | 7/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347030 | 0.90 | TDP1 (0.49) | CYP11B1CYP11B2SMOTDP1KDM4E | |
| SCHEMBL1363389 | 0.88 | CYP11B1 (0.69) | CYP11B1CYP11B2SMONR3C1 | |
| SCHEMBL23535745 | 0.87 | CYP11B1 (0.60) | CYP11B1CYP11B2SMONR3C1KDM4E | |
| SCHEMBL17942269 | 0.84 | CYP11B1 (0.55) | CYP11B1CYP11B2SMONR3C1MAPT | |
| SCHEMBL836030 | 0.83 | CYP11B1 (0.56) | CYP11B1CYP11B2SMONR3C1MAOB | |
| SCHEMBL31632962 | 0.80 | CYP11B2 (0.65) | CYP11B1CYP11B2SMOMAPTALDH1A1 | |
| SCHEMBL3666316 | 0.80 | CYP11B1 (0.54) | CYP11B1CYP11B2MAPTALDH1A1NPBWR1 | |
| SCHEMBL20167005 | 0.78 | CYP11B1 (0.59) | CYP11B1CYP11B2SMONR3C1 | |
| SCHEMBL13486145 | 0.78 | NR3C1 (0.61) | CYP11B1CYP11B2SMONR3C1 | |
| SCHEMBL24976359 | 0.78 | CYP11B1 (0.47) | CYP11B1CYP11B2SMOKDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411001-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20180007907-A1 | PESTICIDALLY ACTIVE SEMI-CARBAZONES AND THIOSEMICARBAZONES DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| US-8569512-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2411001-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2012-01-19 | — | — | US | disclosed |
| WO-2010111060-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180007907-A1 | PESTICIDALLY ACTIVE SEMI-CARBAZONES AND THIOSEMICARBAZONES DERIVATIVES | DDT, ACHE, CAT | CYP11B1 370/4885CYP11B2 365/4885SMO 1852/4885 |
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | CYP11B1 4768/4885CYP11B2 4763/4885SMO 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.